Adverse Events Related to Tirzepatide

CONTEXT: Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved by the US Food and Drug Administration in May 2022 for patients with type 2 diabetes mellitus (T2DM). OBJECTIVE: We aimed to determine the rates of individua...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishra, Rahul, Raj, Rishi, Elshimy, Ghada, Zapata, Isain, Kannan, Lakshmi, Majety, Priyanka, Edem, Dinesh, Correa, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915969/
https://www.ncbi.nlm.nih.gov/pubmed/36789109
http://dx.doi.org/10.1210/jendso/bvad016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915969/
https://www.ncbi.nlm.nih.gov/pubmed/36789109
http://dx.doi.org/10.1210/jendso/bvad016

Ejemplares similares